Neck management in cT1‐2N0 oral squamous cell carcinoma: Act or watchful wait? DOI
Zi‐Zhan Li, Liya Wei, Lei‐Ming Cao

et al.

International Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Abstract The controversy over neck management for cT1‐2N0 OSCC patients has persisted two decades. While selective dissection (SND) been deemed effective, only 30% of actually exhibit lymph node metastasis (LNM). SND‐related complications, such as shoulder dysfunction and lymphedema, significantly impact patient quality life, suggesting that 70% may not benefit from SND. Current guidelines advocate observation, sentinel biopsy (SLNB), SND, but the appropriate scenarios each strategy need further exploration. Risk stratification assessment can inform treatment decisions in early‐stage OSCC. This review explores histological risk factors, SLNB, gene expression profiles, biomarkers stratification. Additionally, we assess potential value postoperative radiotherapy (PORT) immunotherapy, particularly immune checkpoint blockade (ICB), Risk‐stratified approaches align with personalized medicine precision surgery trends, while PORT ICB offer more reliable options. comprehensive systematically synthesizes past selection therapeutic strategies patients, alongside their respective strengths limitations. We aspire to contribute optimization ultimately enhancing both survival outcomes life.

Language: Английский

Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer DOI Creative Commons
Che-Wei Chang,

Szu‐Ting Yang,

Hung‐Hsien Liu

et al.

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(5), P. 651 - 664

Published: Sept. 1, 2024

The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) the cervix. She received six cycles perioperative adjuvant therapy, including three neoadjuvant therapy (NAT) and postoperative by combination dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m

Language: Английский

Citations

15
Neoadjuvant Chemoimmunotherapy for Resectable Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-analysis DOI
Lei‐Ming Cao, Yi-Fu Yu, Zi‐Zhan Li

et al.

Annals of Surgical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Language: Английский

Citations

1
Suicide among patients with oral cancer: A population-based study DOI
Guang-Rui Wang, Hanqi Wang, Nian‐Nian Zhong

et al.

Cancer Epidemiology, Journal Year: 2024, Volume and Issue: 92, P. 102625 - 102625

Published: Aug. 1, 2024

Language: Английский

Citations

8
Neoadjuvant chemoimmunotherapy for locally advanced squamous cell carcinoma of the head and neck: Systematic review and meta-analysis DOI Creative Commons
Xun Zhu, Jie Qiu, Zhang Ya

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: 212, P. 107598 - 107598

Published: Jan. 11, 2025

Neoadjuvant chemoimmunotherapy emerged as a promising treatment for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). However, comparison clinical outcomes with neoadjuvant chemotherapy was lacking. To provide evidence supporting decision-making in LA-SCCHN treatment. Literature retrieved from PubMed, Web Science, Embase, Cochrane Library studies on efficacy safety published before August 10, 2024. The study registered PROSPERO (CRD42024573816). A total 28 trials 2021 patients were included. group had significantly higher pathologic complete response (pCR) (33 % vs. 18 %, P = 0.04) partial (PR) (65 38 < 0.01). No significant differences found overall survival (OS) (hazard ratio: 0.85, 95 CI: 0.77-0.93) progression-free (PFS) 0.72, 0.61-0.86). Regarding outcomes, single-arm trials, grade 3-4 treatment-related adverse events (TRAEs) occurred 14 13 group, 5 TRAEs at 0 4 respectively, showing no difference (P 0.80; 0.08). In both RCTs non-RCT, Risk Ratio (RR) (RR: 1.42, 0.87-2.31). has shown LA-SCCHN, but further randomized are needed to confirm long-term benefits.

Language: Английский

Citations

0
Extracellular Vesicles: Hermes Between Cancers and Lymph Nodes DOI
Lei‐Ming Cao, Yuan-ye Qiu, Zi‐Zhan Li

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217735 - 217735

Published: April 1, 2025

Language: Английский

Citations

0
Neck management in cT1‐2N0 oral squamous cell carcinoma: Act or watchful wait? DOI
Zi‐Zhan Li, Liya Wei, Lei‐Ming Cao

et al.

International Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Abstract The controversy over neck management for cT1‐2N0 OSCC patients has persisted two decades. While selective dissection (SND) been deemed effective, only 30% of actually exhibit lymph node metastasis (LNM). SND‐related complications, such as shoulder dysfunction and lymphedema, significantly impact patient quality life, suggesting that 70% may not benefit from SND. Current guidelines advocate observation, sentinel biopsy (SLNB), SND, but the appropriate scenarios each strategy need further exploration. Risk stratification assessment can inform treatment decisions in early‐stage OSCC. This review explores histological risk factors, SLNB, gene expression profiles, biomarkers stratification. Additionally, we assess potential value postoperative radiotherapy (PORT) immunotherapy, particularly immune checkpoint blockade (ICB), Risk‐stratified approaches align with personalized medicine precision surgery trends, while PORT ICB offer more reliable options. comprehensive systematically synthesizes past selection therapeutic strategies patients, alongside their respective strengths limitations. We aspire to contribute optimization ultimately enhancing both survival outcomes life.

Language: Английский

Citations

0